A recombinant adenovirus that directs secretion of biologically active kappa-bungarotoxin from mammalian cells. 1997

S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
Department of Anesthesia, University of California San Francisco, 94143-0542, USA.

A novel Cre-lox system was used to construct an adenovirus encoding kappa-bungarotoxin (kappa-Bgt), modified to be secreted by attachment of a bovine prolactin signal sequence at the N-terminus of the toxin. Western blot of medium from HEK-293 cells infected with the virus demonstrated that recombinant kappa-Bgt (R-kappa-Bgt) was secreted. The biological activity of the secreted R-kappa-Bgt was investigated in Xenopus oocytes that expressed neuronal nicotinic acetylcholine receptor (nAChR) subtypes alpha3beta2 and alpha2beta2. The recombinant toxin inhibited the response of alpha3beta2 type AChRs to ACh, but did not inhibit the response of alpha2beta2 type AChRs. These data demonstrated that the recombinant adenovirus directs the secretion of biologically active kappa-Bgt from a mammalian cell line. Because adenovirus can be used to infect post-mitotic cells, recombinant adenoviruses encoding biologically active peptides may be of use as delivery vehicles for in vivo experiments where repeated application of the purified peptide is unfeasible.

UI MeSH Term Description Entries
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D011995 Recombination, Genetic Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses. Genetic Recombination,Recombination,Genetic Recombinations,Recombinations,Recombinations, Genetic
D002038 Bungarotoxins Neurotoxic proteins from the venom of the banded or Formosan krait (Bungarus multicinctus, an elapid snake). alpha-Bungarotoxin blocks nicotinic acetylcholine receptors and has been used to isolate and study them; beta- and gamma-bungarotoxins act presynaptically causing acetylcholine release and depletion. Both alpha and beta forms have been characterized, the alpha being similar to the large, long or Type II neurotoxins from other elapid venoms. alpha-Bungarotoxin,beta-Bungarotoxin,kappa-Bungarotoxin,alpha Bungarotoxin,beta Bungarotoxin,kappa Bungarotoxin
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D000256 Adenoviridae A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. Adenoviruses,Ichtadenovirus,Adenovirus,Ichtadenoviruses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014981 Xenopus An aquatic genus of the family, Pipidae, occurring in Africa and distinguished by having black horny claws on three inner hind toes.

Related Publications

S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
February 1997, Journal of hematotherapy,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
August 1992, Protein expression and purification,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
July 2005, Protein expression and purification,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
January 1999, The Journal of biological chemistry,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
October 1995, The Journal of biological chemistry,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
March 2005, Gene therapy,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
May 1991, Gene,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
May 2011, Molecular and cellular biochemistry,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
April 2008, Yonsei medical journal,
S Gorman, and N Viseshakul, and B Cohen, and S Hardy, and G A Grant, and C S Yost, and J R Forsayeth
June 1996, FEBS letters,
Copied contents to your clipboard!